Barbara J. Gitlitz

8.4k total citations · 1 hit paper
118 papers, 4.5k citations indexed

About

Barbara J. Gitlitz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Barbara J. Gitlitz has authored 118 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 69 papers in Pulmonary and Respiratory Medicine and 32 papers in Molecular Biology. Recurrent topics in Barbara J. Gitlitz's work include Lung Cancer Treatments and Mutations (43 papers), Cancer Immunotherapy and Biomarkers (27 papers) and Renal cell carcinoma treatment (18 papers). Barbara J. Gitlitz is often cited by papers focused on Lung Cancer Treatments and Mutations (43 papers), Cancer Immunotherapy and Biomarkers (27 papers) and Renal cell carcinoma treatment (18 papers). Barbara J. Gitlitz collaborates with scholars based in United States, Italy and China. Barbara J. Gitlitz's co-authors include Robert A. Figlin, Arie S. Belldegrun, Allan J. Pantuck, Amnon Zisman, Jonathan Said, Fredrick Dorey, Jean B. deKernion, Debby H. Chao, David R. Gandara and Oleg Shvarts and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Barbara J. Gitlitz

115 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System

2001 542 citations Amnon Zisman, Allan J. Pantuck et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara J. Gitlitz United States	37	2.8k	2.2k	1.9k	855	752	118	4.5k
Sarah Minner Germany	35	1.9k 0.7×	2.0k 0.9×	1.1k 0.6×	1.2k 1.3×	696 0.9×	127	4.2k
Begoña Mellado Spain	36	2.2k 0.8×	2.0k 0.9×	1.9k 1.0×	1.1k 1.3×	947 1.3×	180	4.7k
Noemı́ Reguart Spain	41	2.6k 0.9×	2.5k 1.1×	2.9k 1.5×	875 1.0×	335 0.4×	175	5.5k
Hidetoshi Hayashi Japan	36	2.8k 1.0×	1.4k 0.6×	3.7k 2.0×	705 0.8×	400 0.5×	248	5.2k
Samuel E. DePrimo United States	28	2.5k 0.9×	2.7k 1.2×	2.2k 1.2×	1.3k 1.5×	336 0.4×	40	5.3k
Sang‐We Kim South Korea	36	3.9k 1.4×	1.4k 0.6×	3.5k 1.9×	743 0.9×	353 0.5×	207	5.4k
Makoto Maemondo Japan	37	4.5k 1.6×	1.8k 0.8×	4.3k 2.3×	886 1.0×	340 0.5×	181	6.4k
Manuel Cobo Spain	30	3.4k 1.2×	1.3k 0.6×	3.6k 2.0×	1.1k 1.3×	349 0.5×	219	5.3k
Hiroshi Nokihara Japan	40	3.3k 1.2×	1.7k 0.8×	3.9k 2.1×	935 1.1×	279 0.4×	237	5.9k
Rita Chiari Italy	36	2.4k 0.8×	1.4k 0.6×	2.6k 1.4×	900 1.1×	206 0.3×	140	4.2k

Countries citing papers authored by Barbara J. Gitlitz

Since Specialization

Citations

This map shows the geographic impact of Barbara J. Gitlitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara J. Gitlitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara J. Gitlitz more than expected).

Fields of papers citing papers by Barbara J. Gitlitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara J. Gitlitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara J. Gitlitz. The network helps show where Barbara J. Gitlitz may publish in the future.

Co-authorship network of co-authors of Barbara J. Gitlitz

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara J. Gitlitz. A scholar is included among the top collaborators of Barbara J. Gitlitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara J. Gitlitz. Barbara J. Gitlitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gitlitz, Barbara J., Vinay Duddalwar, Kevin G. King, et al.. (2024). Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma. Oncotarget. 15(1). 444–458.

Wang, Jie, Yun Fan, Jian Fang, et al.. (2024). Abstract CT239: IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC. Cancer Research. 84(7_Supplement). CT239–CT239. 2 indexed citations

Zhou, C., Meghna Das Thakur, Manoj Srivastava, et al.. (2021). 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. Annals of Oncology. 32. S1374–S1374. 41 indexed citations

Gitlitz, Barbara J., Marisa A. Bittoni, Anna Moore, et al.. (2019). P1.14-04 Final Results of the Prospective Genomics of Young Lung Cancer (GYLC), an Addario Lung Cancer Medical Institute Study. Journal of Thoracic Oncology. 14(10). S553–S553. 1 indexed citations

Horn, Leora, Jeffrey R. Infante, Karen L. Reckamp, et al.. (2018). Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clinical Cancer Research. 24(12). 2771–2779. 131 indexed citations

Liu, Stephen V., Susan Groshen, Karen Kelly, et al.. (2018). A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 82(4). 723–732. 5 indexed citations

Rizvi, Naiyer A., David R. Gandara, Benjamin Solomon, et al.. (2018). P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy. Journal of Thoracic Oncology. 13(10). S863–S863. 7 indexed citations

Reckamp, Karen L., Heather A. Wakelee, Sandip Pravin Patel, et al.. (2017). CNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts). Annals of Oncology. 28. ii31–ii32. 3 indexed citations

Cohen, Ezra E.W., Nabil F. Saba, Barbara J. Gitlitz, et al.. (2016). immunotherapy of cancer Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 27. vi573–vi573. 3 indexed citations

10.

Ou, Sai‐Hong Ignatius, Joel Greenbowe, Ziad U. Khan, et al.. (2015). I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer. 88(2). 231–234. 61 indexed citations

11.

Hughes, Brett, Linda Mileshkin, P. Townley, et al.. (2014). Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. The Oncologist. 19(2). 175–176. 19 indexed citations

12.

Gitlitz, Barbara J., Eric Bernstein, Edgardo S. Santos, et al.. (2014). A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(4). 577–582. 29 indexed citations

13.

Sosa, Julie Ann, Rossella Elisei, Barbara Jarząb, et al.. (2013). Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma. Thyroid. 24(2). 232–240. 116 indexed citations

14.

Mileshkin, Linda, Rodney J. Hicks, Brett Hughes, et al.. (2011). Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib. Clinical Cancer Research. 17(10). 3304–3315. 106 indexed citations

15.

Daud, Adil, Smitha Krishnamurthi, Mansoor N. Saleh, et al.. (2011). Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(4). 1092–1100. 68 indexed citations

16.

Lara, Primo N., Jeff Longmate, Karen L. Reckamp, et al.. (2011). Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial. Clinical Lung Cancer. 12(1). 33–37. 17 indexed citations

17.

Chew, Helen K., George Somlo, Philip C. Mack, et al.. (2011). Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Annals of Oncology. 23(4). 1023–1029. 14 indexed citations

18.

Gitlitz, Barbara J., Denice Tsao‐Wei, Susan Groshen, et al.. (2011). A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial. Journal of Thoracic Oncology. 7(3). 574–578. 28 indexed citations

19.

Pantuck, Allan J., Amnon Zisman, Debby H. Chao, et al.. (2003). Renal cell carcinoma with retroperitoneal lymph nodes. Cancer. 97(12). 2995–3002. 128 indexed citations

20.

Hinkel, Andreas, Cho-Lea Tso, Barbara J. Gitlitz, et al.. (2000). Immunomodulatory Dendritic Cells Generated From Nonfractionated Bulk Peripheral Blood Mononuclear Cell Cultures Induce Growth of Cytotoxic T Cells Against Renal Cell Carcinoma. Journal of Immunotherapy. 23(1). 83–93. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact